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Abstract
Introduction We conducted a post-hoc analysis on the effect of
recombinant factor VIIa (rFVIIa) on coagulopathic patients from
two randomized, placebo-controlled, double-blind trials of rFVIIa
as an adjunctive therapy for bleeding in patients with severe
trauma.
Methods Blunt and penetrating trauma patients were randomly
assigned to rFVIIa (200 + 100 + 100 μg/kg) at 0, 1, and 3 hours
after transfusion of 8 units of red blood cells (RBCs) or to
placebo. Subjects were monitored for 48 hours post-dosing and
followed for 30 days. Coagulopathy was retrospectively defined
as transfusion of fresh frozen plasma (FFP) (>1 unit of FFP per
4 units of RBCs), FFP in addition to whole blood, and
transfusion of platelets and/or cryoprecipitate.
Results Sixty rFVIIa-treated and 76 placebo subjects were
retrospectively identified as being coagulopathic. No significant
differences were noted in baseline characteristics. The rFVIIa-
treated coagulopathic subgroup consumed significantly less
blood product: RBC transfusion decreased by 2.6 units for the
whole study population (P = 0.02) and by 3.5 units among
patients surviving more than 48 hours (P < 0.001). Transfusion
of FFP (1,400 versus 660 ml, P < 0.01), platelet (300 versus
100 ml, P = 0.01), and massive transfusions (29% versus 6%,
P < 0.01) also dropped significantly. rFVIIa reduced multi-organ
failure and/or acute respiratory distress syndrome in the
coagulopathic patients (3% versus 20%, P = 0.004), whereas
thromboembolic events were equally present in both groups
(3% versus 4%, P = 1.00).
Conclusion Coagulopathic trauma patients appear to derive
particular benefit from early adjunctive rFVIIa therapy.Page 1 of 11
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aPTT = activated partial thromboplastin time; ARDS = acute respiratory distress syndrome; CI = confidence interval; FFP = fresh frozen plasma; ICU 
= intensive care unit; MOF = multiple organ failure; NNT = numbers needed to treat; PT = prothrombin time; RBC = red blood cell; RCT = randomized 
controlled trial; rFVIIa = recombinant activated factor VII; RRR = relative risk reductions; TBI = traumatic brain injury.
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Trauma is the leading cause of mortality up to the fifth decade
of life [1,2] and uncontrolled hemorrhage is responsible for
approximately 40% of these fatalities [2-5]. Diffuse coagulop-
athy is one of the most challenging situations faced by physi-
cians treating these patients and is associated with high
morbidity and mortality. Coagulopathy is common, affecting as
many as 25% to 36% of trauma victims, and may develop early
after injury [6,7]. It results from factors such as dilution and
consumption of coagulation factors and platelets, fibrinolysis,
acidosis, and hypothermia. Although coagulopathy correlates
with the severity of trauma, it is also an independent risk factor
of mortality [7]. There is little agreement in the contemporary
literature as to the precise definition of coagulopathy in trauma
(Table 1) [6-11]. Because objective measurement of coagu-
lopathy is often unattainable in the clinical setting, current
guidelines recommend empirical replacement therapy for the
coagulopathic patient with diffuse microvascular bleeding
[8,12]. Current management involves replacing coagulation
factors (fresh frozen plasma [FFP], platelets, and cryoprecipi-
tate) and correcting acidosis and hypothermia, steps that
often are insufficient to stop the bleeding and prevent death.
Recombinant activated factor VII (rFVIIa) (NovoSeven®; Novo
Nordisk A/S, Bagsværd, Denmark) is a hemostatic agent that
acts at the site of injury to enhance thrombin generation, lead-
ing to a stable fibrin clot [13,14]. A growing number of case
series and reports have described the safe and effective
hemostatic properties of rFVIIa in trauma patients with uncon-
trolled hemorrhage refractory to conventional therapy [9,15].
These publications have described impressive results with the
use of rFVIIa as a treatment option to control bleeding in high-
risk, actively bleeding patients in various situations, including
trauma [9,15,16], severe postpartum hemorrhage [17,18],
and cardiac surgery [19-21]. Recently, our group published
the first multi-center, international, randomized, placebo-con-
trolled, double-blind study of rFVIIa in trauma and demon-
strated that it is a safe and efficacious adjunctive therapy in
controlling hemorrhage [22]. Considering that the majority of
the patients in this study had evidence of being coagulopathic
at the time of rFVIIa administration, we hypothesized that rFVIIa
might have a particularly beneficial role in the treatment of dif-
fuse coagulopathy that results from severe trauma.
To test this hypothesis, we carried out a post-hoc analysis of a
subgroup of patients from the randomized prospective trial,
who based on the clinical requirement for replacement therapy
were identified as having coagulopathy.
Materials and methods
The study protocol was approved by the ethics committee of
each participating institution (see Appendix), and the trial was
conducted according to Good Clinical Practice standards and
the Helsinki Declaration. Written informed consent was
obtained from all patients or, where applicable, from a legally
authorized representative. Due to the emergency conditions
and the possible absence of relatives at enrolment in the trial,
ethics committees authorized waived informed consent. How-
ever, whenever a patient was included without written
informed consent, such consent was promptly solicited from a
legally authorized representative and subsequently from the
patient.
Table 1
Definitions of coagulopathy in the recent trauma literature
Laboratory parameters Source
PT ≥1.5 N (0) 1.5–2 N (1) >2 N (2) Mayo et al., 2004 [11]
PTT ≥1.5 N (0) 1.5–2 N (1) >2 N (2)
Plt >100 (0) 50–100 (1) ≥50 (2)
Fib >100 (0) 50–100 (1) ≥50 (2)
Total: 0 mild, 1–3 moderate, 4–8 severe
INR >1.4 or Plt <100,000 or both Dutton et al., 2004 [9]
PT >18 seconds or PTT >60 seconds or TT >15 seconds Brohi et al., 2003 [6]
PT >14 seconds or PTT >34 seconds MacLeod et al., 2003 [7]
PT >15 seconds or PTT >45 seconds or Fib <100 Vaslef et al., 2002 [37]
PT or PTT twice normal Cosgriff et al., 1997 [10]
PT or PTT >1.5–1.8 times control values Stehling et al., 1996 [8]
Ongoing bleeding, oozing from cut surfaces, catheters, or mucous membranes Lynn et al., 2002 [31]
Fib, fibrinogen; INR, international normalized ratio; N, normal; Plt, platelet; PT, prothrombin time; PTT, partial thromboplastin time; TT, thrombin 
time.Page 2 of 11
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Briefly, to be eligible for inclusion, patients were to have
received 6 units of red blood cells (RBCs) within a four hour
period and to be of known age of at least 16 years (or legally
of age according to local law) and less than 65 years. Key
exclusion criteria were cardiac arrest pre-hospital or in the
emergency or operating rooms prior to trial drug administra-
tion; gunshot wound to the head; Glasgow Coma Scale of
less than 8 unless in the presence of a normal computed tom-
ography scan of the head; base deficit of more than 15 mEq/l
or severe acidosis with pH of less than 7.00; transfusion of 8
or more units of RBCs prior to arrival to the trauma center; and
injury sustained 12 or more hours before randomization.
This was a randomized, placebo-controlled, double-blind trial
with two parallel treatment arms in two separate trauma popu-
lations (blunt and penetrating traumas). Upon receiving 6 units
of RBCs within a four hour period, eligible patients within each
trauma population were equally randomly assigned to receive
either three intravenous injections of rFVIIa (200, 100, and
100 μg/kg) or three placebo injections. The first dose of trial
product was to be administered immediately after transfusion
of the eighth unit of RBCs, given that the patient (in the opinion
of the attending physician) would require additional transfu-
sions. The second and third doses followed one and three
hours after the first dose, respectively. Trial product was
administered in addition to standard treatment for injuries and
bleeding at the participating hospitals, and no restrictions
were imposed on procedures deemed necessary by the
attending physician, including surgical interventions, resusci-
tation strategies, and use of blood products. To reduce the dif-
ferences in standards of care between countries and
institutions, each participating trauma center had to develop
specific transfusion guidelines in line with the transfusion
guidelines provided in the study protocol.
Subgroup selection
Patients included in the two arms of the trial (blunt and pene-
trating traumas) were pooled together. Because it was not
possible to objectively determine a patient's coagulopathic
status at study entry (due to the lack of a consensus laboratory
definition for coagulopathy, time constraints, and limitations of
laboratory testing in a trauma setting), a post-hoc state of
coagulopathy was defined based on current transfusion
guidelines [8]. For the purpose of the present analysis, coag-
ulopathic patients were identified using the following defini-
tion: an ongoing bleeding that required the use of transfusion
with FFP and RBC units at a ratio of 1 or more units of FFP for
every 4 units of RBCs, and/or the use of FFP with whole blood,
and/or transfusion of platelets, and/or the transfusion of cryo-
precipitate. This definition was used because no consensus
definition currently exists that adequately defines coagulopa-
thy. Because traumatic brain injury (TBI) mandates a different
fluid and transfusion management, carries a higher risk for
coagulopathy, and has outcomes that are distinctive from
other polytrauma patients, patients with TBI were also
excluded from this analysis [23]. A flowchart of the present
study is depicted in Figure 1.
Endpoints
The primary endpoint was the number of RBC units (alloge-
neic RBCs, autologous RBCs, and whole blood) transfused
during the 48-hour period after the first dose of trial product,
as previously described [22]. Outcome of therapy was further
assessed through requirement for other transfusion products,
massive transfusion (defined as more than 20 units of RBCs
inclusive of the 8 pre-dose units), time on ventilator, time in the
intensive care unit (ICU), and serious adverse events, includ-
ing the predefined critical complications of multiple organ fail-
ure (MOF), acute respiratory distress syndrome (ARDS), and
death, all recorded until day 30. Because mortality is not a sen-
sitive variable in a trauma population, we also studied a com-
posite endpoint that comprised death, MOF, and ARDS,
repeating the analysis performed in the original randomized
controlled trial (RCT) [24,25]. To enable us to compare the
durations of hospitalization and of ICU admission while taking
into account mortality rates, we calculated the number of hos-
pital-free days and ICU-free days within one month after
trauma, with all deceased patients being given a score of 0
hospital- or ICU-free days, as previously described [26].
Separate analyses were performed in which patients who died
within 48 hours were excluded, as previously described [22].
Patients who died within 48 hours were excluded because in
a large proportion of these patients, care was futile and 48-
hour transfusion requirements could not be objectively
assessed for patients who were alive for only a few hours.
Statistical analysis
Data are expressed as mean ± standard deviation or as
median and range. All statistical comparisons were two-tailed,
and P less than 0.05 was considered significant. Comparison
between the two groups was performed using the Wilcoxon-
Mann-Whitney rank sum tests for continuous outcomes (trans-
fusions, time on ventilator, and time in ICU), and Fisher's exact
test was used for binary outcomes (massive transfusion, MOF,
ARDS, and mortality). The differences between groups were
estimated by the Hodges-Lehman shift with 95% confidence
interval (CI) for continuous outcomes, and relative risk reduc-
tions (RRR) and numbers needed to treat (NNT) with 95% CIs
were used for the binary outcomes. Patients who died within
48 hours were assigned highest rank (worst outcome) in the
Mann-Whitney test and in the Hodges-Lehman estimation.
Results
Of the 277 randomly assigned patients eligible for analysis, 30
were excluded from evaluation because of TBI and seven oth-
ers for insufficient data on their coagulopathic status. Thus,
using the defined criteria for coagulopathy, the subgroup of
coagulopathic patients comprised a total of 136 patients, 76Page 3 of 11
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rFVIIa (Figure 1). A comparative overview of baseline charac-
teristics of the selected coagulopathic patient subgroup,
according to the defined criteria, versus the non-coagulo-
pathic patients is depicted in Table 2.
Baseline characteristics were broadly concordant between
non-coagulopathic and coagulopathic patients, with the
exception of significant differences in the use of FFP, platelets,
and cryoprecipitate (the basis for the definition of coagulopa-
thy) and differences in hematocrit, prothrombin time (PT) and
pH (also reflective of coagulopathy), and injury severity score
(Table 2). Of note, the two groups had similar baseline labora-
torial coagulation profiles, including activated partial thrombo-
plastin time (aPTT), PT, platelet count, and fibrinogen levels.
Table 2 also provides data on the use of FFP, platelets, and
cryoprecipitate from time of administration of trial drug to 48
hours.
The remaining analysis will focus exclusively on the coagulo-
pathic patients. The baseline characteristics of injury severity
score and physiological and coagulation variables were com-
parable between the placebo- and rFVIIa-treated coagulo-
pathic patient groups, with no significant differences between
groups (Table 3).
rFVIIa significantly reduced 48-hour RBC requirements by 2.6
units (all patients) and 3.5 units (48-hour survivors) compared
with placebo (Table 4). Irrespective of whether the analysis
included all or only 48-hour survivors, the need for FFP was
also significantly reduced by rFVIIa treatment whereas platelet
requirement was significantly reduced only among the 48-hour
survivors (Table 4). Massive transfusion was found to be sig-
nificantly reduced in patients surviving more than 48 hours
who received rFVIIa as compared with placebo (P = 0.003,
RRR 79%, 95% CI 32% to 93%) (Figure 2) but not when all
patients were included. Treatment with rFVIIa was associated
with an even greater reduction in exposure to RBCs, FFP, and
platelets in patients surviving more than 48 hours (Table 4). In
these patients, all blood-product requirements were more than
halved in the rFVIIa group.
The summation of the baseline characteristics (including
causes of death) of the coagulopathic patients who died early
(<48 hours) is presented in Table 5. Placebo and rFVIIa
groups were similar in all aspects except for a higher preva-
Figure 1
Trial profile. The figure shows the number of penetrating and blunt trauma patients eligible in the two groups (placebo and recombinant activated 
factor VII [rFVIIa]), the exclusion of patients because of traumatic brain injury (TBI) and insufficient data concerning the coagulopathic state, and the 
number of patients finally adjudicated to the placebo and rFVIIa analysis. RBC, red blood cells.Page 4 of 11
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Sixteen of the 21 early deaths (76%) were due to exsanguina-
tion, indicating that failure to halt bleeding in patients trans-
fused with 8 units of RBCs in the first hours is often fatal. Of
note, the patients who died early had a markedly prolonged
aPTT/PT but not as abnormal a platelet count or fibrinogen
level.
Results for investigator-reported clinical complications and
mortality within 30 days are summarized in Table 6. Treatment
with rFVIIa significantly reduced the incidence of ARDS
among all coagulopathic patients (P = 0.04, RRR 86%, 95%
CI 0% to 98%, NNT 9.83, 95% CI NNT 5.15 to 88.25) and
among patients surviving more than 48 hours (P = 0.04, RRR
85%, 95% CI 0% to 98%). rFVIIa also significantly reduced
the combined endpoint of MOF and/or ARDS among all coag-
ulopathic patients (P = 0.004, RRR 83%, 95% CI 29% to
96%, NNT 6.10, 95% CI NNT 3.71 to 18.23) and among
patients surviving more than 48 hours (P = 0.004, RRR 90%,
95% CI 23% to 99%) (Table 6).
Discussion
In trauma patients with coagulopathic hemorrhage, rFVIIa is
emerging as a potentially valuable new damage-control tool for
use when hemorrhage is refractory to standard-of-care treat-
ment [9,15,22,27-30]. The analysis reported here is based on
data from two randomized parallel controlled trials in severely
injured patients [22]. In these trials, rFVIIa reduced the need
for blood transfusion in blunt trauma patients surviving for 48
hours and with a trend toward less RBC transfusion in patients
with penetrating trauma. At study entry, it was not possible to
identify this coagulopathic subgroup of patients, because
available routine laboratory testing (aPTT, PT, platelet count,
and fibrinogen levels) did not accurately identify clinically sig-
nificant coagulopathic bleeding. The platelet count does not
reflect platelet-impaired function such as in hypothermia and
acidosis, typically present in the massively bleeding trauma
victim [31]. PT and aPTT are poor predictors of clinical bleed-
ing unless a marked prolongation (that is, prolongation beyond
the limit of machine measurements) is observed [30]. Because
blood samples are typically re-warmed to 37°C, there is an
underestimation of coagulopathy in hypothermic conditions
typical of critical trauma patients [31]. In addition, the time
required for these routine tests as well as for a more thorough
analysis of coagulation state to be performed – approximately
45 minutes – precludes an accurate 'real time' reflection
because the patients are usually massively transfused and
infused during the time period elapsing between sampling to
Table 2
Baseline characteristics of coagulopathic and non-coagulopathic patients
Coagulopathic patients (n = 136) Non-coagulopathic patients (n = 104) P value
RBCs prior to trial drug, units (n) 8.4 ± 1.6 (134) 8.4 ± 1.4 (98) 1.00
FFP prior to trial drug, ml (n) 922 ± 627 (102) 95 ± 178 (88) <0.001
Platelets prior to trial drug, ml (n) 126 ± 181 (128) 0 ± 0 (100) <0.001
Cryoprecipitate prior to trial drug, ml (n) 28 ± 78 (135) 0 ± 0 (104) <0.001
FFP after trial drug to 48 hours, ml (n) 1,596 ± 1,777 (102) 1,499 ± 1,927 (88) 0.72
Platelets after trial drug to 48 hours, ml (n) 289 ± 341 (127) 319 ± 432 (100) 0.57
Cryoprecipitate after trial drug to 48 hours, ml (n) 56 ± 151 (135) 33 ± 121 (104) 0.19
Injury severity score (n) 30 ± 13 (131) 26 ± 13 (104) 0.02
Temperature, °C (n) 35.1 ± 1.4 (92) 35.2 ± 1.5 (62) 0.68
Mean arterial pressure, mm Hg (n) 76 ± 22 (132) 74 ± 18 (101) 0.45
pH (n) 7.28 ± 0.11 (130) 7.24 ± 0.12 (101) 0.01
Hematocrit, percentage (n) 25 ± 8 (104) 28 ± 9 (83) 0.02
aPTT, seconds (n) 50 ± 25 (79) 54 ± 30 (51) 0.43
PT, seconds (n) 19 ± 6 (90) 21 ± 6 (58) 0.05
Platelet count, × 109 (n) 78 ± 45 (122) 70 ± 47 (98) 0.20
Fibrinogen, g/l (n) 1.3 ± 0.7 (90) 1.2 ± 1.2 (58) 0.57
48-hour mortality, n (percentage) 21 (15) 20 (19) 0.44
30-day mortality, n (percentage) 32 (24) 29 (28) 0.44
Data are mean ± standard deviation or number (percentage). aPTT, activated partial thromboplastin time; FFP, fresh frozen plasma; PT, 
prothrombin time; RBC, red blood cell.Page 5 of 11
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ratory standards for the definition of coagulopathy in these
severely traumatized patients (see Table 1 for a summary of
differing definitions found in the trauma literature), the clinical
diagnosis of coagulopathy is familiar to most intensivists and
surgeons. This is characterized by the clinical assessment of
ongoing bleeding and the observation of oozing from cut sur-
faces, intravascular catheter sites, or mucus membranes [31].
Our post-hoc analyses identified patients who were believed
by their treating physicians to have clinically significant coagu-
lopathic bleeding, as reflected by the empirical replacement
therapy that was administered. In this group, treatment with
rFVIIa significantly reduced the need for all blood products,
surrogate markers of bleeding, as well as potential donor expo-
sure as compared with placebo during standard-of-care man-
agement of hemorrhage (Table 4). Furthermore, in these
coagulopathic patients, early adjunctive treatment with rFVIIa
had a significant effect on the risk for developing MOF and
ARDS in the 30 days after traumatic injury (Table 5).
Our analyses of data also identified a significant effect of
rFVIIa treatment on patients' requirement for massive RBC
transfusion in the first 48 hours of the study in patients surviv-
ing more than 48 hours. Approximately 29% of coagulopathic
patients in the placebo group required an additional 12 units
of RBC transfusion (to the initial 8 units prior to trial drug) to
manage ongoing hemorrhage as compared with a much-
reduced need for massive transfusion in the rFVIIa-treated
coagulopathic group, in which only 6% of patients required
this level of transfusion (Figure 2). Massive transfusion of this
type – 20 units of RBCs administered from time of injury to
assessment at 48 hours after study entry – represents ongo-
ing hemorrhage equivalent to at least two blood volumes
[32,33]. The effect of rFVIIa to arrest such massive blood loss
reduces patient exposure to excessive transfusion of blood
Table 3
Baseline clinical and biological characteristics of coagulopathic patients in the placebo and rFVIIa groups
Placebo group (n = 76) rFVIIa group (n = 60)
Age (years) 34 ± 12 31 ± 11
Gender
Men 63 (83%) 51 (85%)
Women 13 (17%) 9 (15%)
Type of trauma
Penetrating 38 (50%) 35 (58%)
Blunt 38 (50%) 25 (42%)
Injury severity score 30 ± 13 30 ± 13
Number of body regions injured
1 16 (21%) 13 (22%)
2–3 40 (53%) 29 (48%)
>3 18 (24%) 17 (28%)
Unknown 2 (3%) 1 (2%)
Systolic blood pressure (mm Hg) 103 ± 26 109 ± 31
Mean arterial pressure (mm Hg) 74 ± 22 78 ± 23
Body temperature (°C) 35.2 ± 1.6 35.6 ± 1.1
pH 7.27 ± 0.11 7.29 ± 0.10
Hematocrit (percentage) 23 ± 8 26 ± 7
aPTT (seconds) 54 ± 24 46 ± 26
PT (seconds) 20 ± 5 17 ± 7
Fibrinogen (g/l) 1.3 ± 0.8 1.4 ± 0.6
Platelets (× 109) 70 ± 42 87 ± 47
Data are mean ± standard deviation or number (percentage). No significant statistical differences between groups were observed. aPTT, activated 
partial thromboplastin time; PT, prothrombin time; rFVIIa, recombinant activated factor VII.Page 6 of 11
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tious risks. It is known that with increasing transfusion require-
ments, there is a greater risk of morbidity and potentially fatal
complications associated with traumatic hemorrhage. This
may be due in part to a correlation between the severity of
trauma and transfusion needs but also in part to the negative
effects of transfusions per se. Indeed, the risk of developing
ARDS and MOF after trauma has been shown to correlate with
increasing transfusion requirements [34,35]. Our analysis of
data from coagulopathic patients treated with adjunctive
rFVIIa revealed a significant improvement in clinical outcome
as compared with placebo. Significant reductions in the com-
bined endpoint of ARDS and/or MOF were seen in rFVIIa-
treated subjects at day 30, when these complications
occurred in just 3% of patients as compared with a rate for
ARDS and/or MOF of one out of every five placebo-treated
coagulopathic subjects (Table 5).
RFVIIa significantly reduced the incidence of ARDS among all
patients. Considering only the patients surviving more than 48
hours, ARDS (2%) or the combined endpoint of ARDS and/or
MOF (2%) and the combined endpoint of ARDS/MOF/death
(6%) were also significantly reduced up to day 30 in the group
that received rFVIIa treatment, in contrast to a 14% rate of
ARDS, a 20% rate of ARDS or MOF, and a 23% rate of death,
MOF, or ARDS in placebo-treated subjects over the same fol-
low-up period. Within this subgroup, it was shown that treat-
ment with rFVIIa was particularly beneficial in effecting a
reduction in the primary clinical endpoint of RBC requirements
during 48 hours (Table 4). We noted a 3.5-unit reduction in
RBC transfusion associated with treatment. The reductions in
RBC requirement in this subgroup were accompanied by a
similar reduction in FFP of 800 ml and reduced platelet
requirements of 50 ml, in essence halving transfusion require-
ments (Table 4).
This study was designed with the intent of being hypothesis-
generating and has limitations that deserve comment. It is a
post-hoc analysis of the only RCT on the use of rFVIIa in
trauma to date. The original RCT has pitfalls, some of which
are inherent to clinical trials designed to study severely trauma-
tized and actively bleeding patients during the earliest and
most acute phase of resuscitation. One limitation was the dif-
ficulty of establishing uniform standards of care among 23 dif-
ferent institutions spread across eight countries. The original
trial elected to use blood transfusion as a surrogate marker of
bleeding, a widely accepted but still imperfect marker.
Figure 2
Comparison of the proportion of patients (all coagulopathic patients as well as coagulopathic atients surviving more than 48 hours) requiring massive tr sfusion
well as coagulopathic patients surviving more than 48 hours) requiring 
massive transfusion. Massive transfusion was defined as more than 12 
red blood cell (RBC) units within 48 hours of the first dose, which 
equals more than 20 units of RBCs (inclusive of the 8 pre-dose units) in 
the placebo and recombinant activated factor VII (rFVIIa) groups.
Table 4
Transfusion requirements during the 48 hours after the first dose of trial drug in the placebo and rFVIIa groups
Placebo group rFVIIa group
n Median (range) n Median (range) Differences in medians Estimated reduction:
median of differences (95% CI)a
P valueb
RBC (units)
All patients 76 6.5 (0–41) 60 4.4 (0–39.9) 2.1 2.6 (0.1; 5.1) 0.02
Alive at 48 hours 65 6.6 (0–41) 48 2.9 (0–20) 3.7 3.5 (1.7; 5.7) <0.001
FFP (ml)
All patients 60 1,360 (0–6,912) 42 705 (0–9,000) 655 600 (0.00; 1,320) 0.04
Alive at 48 hours 54 1,400 (0–6,912) 35 660 (0–9,000) 740 800 (250.0; 1,420) 0.001
Platelets (ml)
All patients 72 300 (0–1,500) 55 147 (0–1,200) 153 50 (0; 250) 0.09
Alive at 48 hours 62 300 (0–1,500) 46 100 (0–900) 200 50 (0; 250) 0.01
aThe Hodges-Lehman shift with 95% CI. Patients who died within 48 hours were assigned the highest rank for the Wilcoxon-Mann-Whitney test 
and the Hodges-Lehman estimate. bTwo-sided Wilcoxon-Mann-Whitney rank sum test. CI, confidence interval; FFP, fresh frozen plasma; RBC, red 
blood cell; rFVIIa, recombinant activated factor VII.Page 7 of 11
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trauma patients separately, considering the smaller patient
sample of coagulopathic patients available, the present study
analyzed all coagulopathic patients combined, irrespective of
the mechanism of injury. The definition of coagulopathy used
is limited and imperfect because it permits a patient diagnosed
as coagulopathic but for any reason not treated with blood
products to be excluded from this analysis. In addition, the
expectation was that coagulopathy secondary to either blunt
or penetrating trauma would equally respond (or not) to the
intervention. The present study also analysed the data both
including all patients and excluding those who died early, thus
repeating the analysis performed in the original RCT.
Despite the limitations, the findings of our post-hoc analysis of
a subgroup of patients support the premise that rFVIIa is a val-
uable addition to the therapeutic armamentarium in the man-
agement of severe trauma, helping to arrest life-threatening
coagulopathic hemorrhage, reducing transfusion require-
ments and associated risks, and having the potential to impact
on the longer term morbidity and mortality associated with
traumatic bleeding [9,15,22,27,28,36]. Moreover, our analysis
identified clinically coagulopathic patients as the high-risk
group of trauma patients who might benefit the most from
rFVIIa therapy. Considering the limited therapeutic options
and the high mortality associated with post-traumatic diffuse
coagulopathy, this study supports the validity of considering
Table 5
Baseline clinical and biological characteristics of coagulopathic patients who died early (within 48 hours)
Placebo group rFVIIa group
(n = 10) (n = 11)
Age (years) 39 ± 12 30 ± 9
Gender
Men 7 (70%) 11 (100%)
Women 3 (30%) 0 (0%)
Type of trauma
Penetrating 4 (40%) 8 (73%)
Blunt 6 (60%) 3 (27%)
Injury severity score 34 ± 13 37 ± 8
Number of body regions injured
1 1 (10%) 2 (18%)
2–3 6 (60%) 7 (64%)
>3 3 (30%) 2 (18%)
Unknown 0 (0%) 0 (0%)
Systolic blood pressure (mm Hg) 87 ± 22 103 ± 34
Mean arterial pressure (mm Hg) 63 ± 17 68 ± 32
Body temperature (°C) 34.1 ± 2.5 35.2 ± 1.2
pH 7.28 ± 0.10 7.23 ± 0.09
Hematocrit (percentage) 26 ± 14 19 ± 4
aPTT (seconds) 93 ± 44 78 ± 32
PT (seconds) 25 ± 6 25 ± 7
Fibrinogen (g/l) 0.8 ± 0.3 0.7 ± 0.3
Platelets (× 109) 42 ± 51 61 ± 35
Causes of death
Exsanguination 7 (70%) 9 (82%)
Organ failure 3 (30%) 1(9%)
Cardiac injury 0 (0%) 1 (9%)
aPTT, activated partial thromboplastin time; PT, prothrombin time; rFVIIa, recombinant activated factor VII.Page 8 of 11
(page number not for citation purposes)
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ever, the hypothesis generated by this post-hoc analysis
requires corroboration from other studies before any definitive
recommendation can be advised.
Conclusion
This post-hoc analysis supports the assertion that coagulopa-
thy is common in patients with severe trauma. Of the 277
trauma patients included in a clinical trial after receiving 8 units
of RBCs, 49% were identified as coagulopathic (136
patients). There is, however, little agreement on a diagnosis for
traumatic coagulopathy or on its objective measurement.
The results of this study suggest that the subgroup of coagu-
lopathic trauma patients receive particular benefit from rFVIIa
therapy. Compared to a control group, coagulopathic patients
treated with rFVIIa required significantly less blood transfusion
with reductions in RBCs, FFP, platelets, and massive transfu-
sions. The use of rFVIIa led to a reduction in ARDS and/or
MOF and did not increase thromboembolic complications.
Considering the mortality and limited therapeutic options, this
study supports the concept of considering rFVIIa for the man-
agement of trauma patients with coagulopathy.
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